INSYS Therapeutics Inc. (INSY)

0.30
0.01 4.52
OTC : Health Technology
Prev Close 0.29
Open 0.28
Day Low/High 0.28 / 0.32
52 Wk Low/High 0.14 / 11.65
Volume 1.09M
Avg Volume 3.70M
Exchange OTC
Shares Outstanding 74.57M
Market Cap 21.71M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

INSYS Therapeutics Initiates Phase 3 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Infantile Spasms

Pivotal study aims to evaluate safety and efficacy of company's novel CBD product candidate in rare type of pediatric epilepsy

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

First Week of April 20th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

First Week of March 16th Options Trading For Insys Therapeutics (INSY)

First Week of March 16th Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

INSY Crosses Above Average Analyst Target

INSY Crosses Above Average Analyst Target

In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $12.75, changing hands for $13.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.

First Week of August 2018 Options Trading For Insys Therapeutics (INSY)

First Week of August 2018 Options Trading For Insys Therapeutics (INSY)

Investors in Insys Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

INSYS Therapeutics Initiates Phase 2 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Refractory Childhood Absence Epilepsy In Pediatric Patients

INSYS Therapeutics Initiates Phase 2 Clinical Trial Of Cannabidiol (CBD) Oral Solution For Treatment Of Refractory Childhood Absence Epilepsy In Pediatric Patients

Proof-of-concept study aims to assess efficacy, safety, tolerability and pharmacokinetics of company's novel CBD product candidate

INSYS Therapeutics Starts Proof-of-Concept Study Of Epinephrine Nasal Spray For Anaphylaxis

INSYS Therapeutics Starts Proof-of-Concept Study Of Epinephrine Nasal Spray For Anaphylaxis

Using standard intramuscular injection as comparator, company's Phase 1 clinical trial enrolls first patient

FDA Accepts New Drug Application (NDA) For Buprenorphine Sublingual Spray From INSYS Therapeutics

FDA Accepts New Drug Application (NDA) For Buprenorphine Sublingual Spray From INSYS Therapeutics

Novel formulation of partial opioid offers potential benefits compared to current alternatives

Interesting INSY Put And Call Options For January 2018

Interesting INSY Put And Call Options For January 2018

Investors in Insys Therapeutics Inc saw new options become available this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

INSYS Therapeutics Reports Third Quarter 2017 Results

INSYS Therapeutics Reports Third Quarter 2017 Results

Official Launch of SYNDROS® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives

INSYS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Insys Therapeutics, Inc. To Contact The Firm

INSYS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Insys Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insys Therapeutics, Inc.